Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Go back to Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.15 +0.36 (0.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.79 | 52 Week High | $118.49 | |||
| Open | $115.04 | 52 Week Low | $55.00 | |||
| Day High | $117.47 | P/E | N/A | |||
| Day Low | $114.51 | EPS | $-0.56 | |||
| Volume | 398,046 | |||||
